期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

静脉补充铁剂对早产儿铁储存的影响 被引量：3

原文传递
导出
摘要 目的研究静脉补充铁剂对早产儿铁储存状况的改善程度。方法将需要肠外营养(PN)的早产儿56例随机分为对照(不含铁)组、含铁1组(蔗糖铁100μg·kg-1·d-1)、含铁2组(蔗糖铁200μg.kg-1.d-1)3组。每组PN应用时间14 d。铁剂加入PN中慢速输注。每例入选早产儿在PN前后分别检测铁储存指标[铁蛋白(SF),血清铁(SI),总铁结合力(TIBC)、转铁蛋白饱和度(TS)],统计分析组内及组间是否有差异,探讨静脉补充铁剂是否对早产儿铁储存有影响。结果与干预前比较,含铁2组SI、SF和TS显著升高,TIBC显著降低(均P<0.01);而含铁1组和对照组除TS显著升高(均P<0.01)外,其余各项指标的差异均无统计学意义(均P>0.05)。3组间比较,干预后除TIBC含铁2组显著低于对照组(P<0.01)外,其余各项指标3组间的差异均无统计学意义(均P>0.05)。结论含铁200μg·kg-1·d-1的PN可改善早产儿的铁储存指标。
作者 乔林霞 朱文英 王华
机构地区 江苏大学附属昆山第一人民医院儿内科
出处 《苏州大学学报（医学版）》 CAS 2012年第4期587-589,共3页 Suzhou University Journal of Medical Science
基金 昆山市社会发展科技计划项目(KS1124)
关键词 早产儿 贫血 铁储存 铁剂
分类号 R722.6 [医药卫生—儿科]
  • 相关文献

参考文献10

  • 1李月梅.促红细胞生成素在早产儿贫血治疗中的研究进展[J].新生儿科杂志,2002,17(4):188-190. 被引量：23
  • 2郭志荣,蒋国雄,周永兰.妊娠期贫血与早产、低出生体重关系的meta分析[J].苏州大学学报（医学版）,2003,23(3):373-377. 被引量：13
  • 3乔林霞,汤庆娅,费延文,王莹.儿科用静脉营养液中加入蔗糖铁对脂肪乳剂稳定性的影响[J].中华临床营养杂志,2010,18(2):111-114. 被引量：5
  • 4Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin treated premature infants [ J]. Pediatrics,2001,107 ( 1 ) : 78 - 85.
  • 5Julia C. Adverse events associated with intravenous iron in- fusion (low-molecular-weight iron dextran and iron su- crose) :a systematic review [ J ]. Transfusion Alternatives in Transfusion Medicine, 2007,9( 1 ) : 8 - 36.
  • 6Friel JK, Andrews WL, Hall MS, et al. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition[ J]. J Parenter Enteral Nutr, 1995,19(2) :114 - 118.
  • 7Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythro poietin and prematurity: where do we stand [ J ]. Perinat Med, 2005,33 (4) :277 - 286.
  • 8Surico G, Muggeo P, Muggeo V,et al. Parenteral iron sup- plementation for the treatment of iron deficiency anemia in children [ J ]. Ann Hemato1,2002,81 ( 1 ) : 154 - 157.
  • 9Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of re- combinant human erythropoietin in critically il1 patients: a randomized controlled trial [ J ]. JAMA, 2002, 288 (2) : 2827 - 2835.
  • 10Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients [J]. J Am Soc Nephrol, 2000, 11(3) :530 -538.

二级参考文献42

  • 1[1]Reiter PD, Rosenberg AA, Valuck RJ. Factors associated with successful epoetin alfa therapy in premature infants. Ann Pharmacother, 2000,34:433-439.
  • 2[2]Donato H, Vain N, Rendo P, et al. Effect of early versus late adiministration of human recombinant erythropoietin on transfusion requirements in premature infants: results of a randomized,placebo-controlled, multicenter trial. Pediatrics, 2000, 105:1066-1072.
  • 3[3]Pollak A, Hayde M, Hayn M, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics,2001,107:78-85.
  • 4[4]Juul SE. Erythropoietin in the neonate. Curr Probl Pediatr,1999,29:129-149.
  • 5[5]Dame C, Fahnenstich H, Freitag P, et al. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood,1998;92:3218-3225.
  • 6[6]Adamson JW. Regulation of red blood cell production. Am J Med, 1996,101 (2A) :46-6S.
  • 7[7]Strauss RG. Recombinant erthropoietin for the anemia of prematurity: still a promise, not a panacea. J Pediatr, 1997; 131:653-655.
  • 8[8]Carnielli VP, Riol RD, Montini G. Iron supplementation enhances response to high doses of recombinant human ergthropoietin in preterm infants. Arch Dis Child, 1998,79:F44-F48.
  • 9[9]Maier RF, Obladen M, Kattner E, et al. High-versus low-dose erythropoietin in extremely low birth weight infants. J Pediatr,1998; 132:866-870.
  • 10[10]Rondini G, Chirioco G. Hematopoietic growth factor levels in term and preterm infants. Curr Opin Hematol, 1999,6: 192-197.

共引文献38

同被引文献30

  • 1杨俊,秦环龙.全自动配液仪对营养液中脂肪乳剂稳定性影响的研究[J].肠外与肠内营养,2006,13(3):176-178. 被引量：4
  • 2Sobotka L.临床营养基础[M].3版.上海:复旦大学出版社,2007.
  • 3Chertow GM, Mason PD, Vaage-Nilsen O, et al. On the relative safety of parenteral iron formulations [ J ]. Nephrol Dial Trans- plant, 2004, 19 (6) : 1571-1575.
  • 4Tu YH, Knox NL, Biringer JM, et al. Compatibility of iron dex- tran with total nutrient admixtures [ J ]. Am J Hosp Pharm,1992, 49 (9) : 2233-2235.
  • 5Mayhew SL, Quick MW. Compatibility of iron dextran with neo- natral parenteral nutrient solutions [ J ]. Am J Health Syst Pharm, 1997, 54 (5): 570-571.
  • 6Friel JK, Andrews WL, Hall MS, et al. Intravenous iron admin- istration to very-low-birth-weight newborns receiving total and partial parenteral nutrition [J]. JPEN J Parenter Enteral Nutr, 1995, 19 (2): 114-118.
  • 7Silverstein SB, Rodgers GM. Parenteral iron therapy options [J]. AmJHematol, 2004, 76 (1):74-78.
  • 8Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on ad- verse drug events associated with parenteral iron [ J ]. Nephrol Dial Transplant, 2006, 21 (2) : 378-382.
  • 9Koletzko B, Goulet O, Hunt J, et al. Guidelines on paediatric parenteral nutrition [ J]. J Pediatr Gastroenterol Nutr, 2005, 41 (2) : S1-$87.
  • 10Vaughan LM, Small C, Plunkett V. Incompatibility of iron dex- tran and a total nutrient admixture [ J ]. Am J Hosp Pharm, 1990, 47 (8): 1745-1746.

引证文献3

二级引证文献23

苏州大学学报（医学版）
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部